Ivor (Bemiparin Sodium)

Bemiparin Sodium is indicated for anticoagulation in several venous thromboembolic conditions.

• Deep vein thrombosis (post‑orthopedic surgery): prevents clot formation after procedures such as hip or knee replacement.
• Venous thromboembolism prophylaxis (at‑risk patients): reduces incidence of DVT and pulmonary embolism in medically immobilized individuals.
• Acute deep vein thrombosis treatment: facilitates clot resolution and prevents extension in diagnosed DVT cases.

• Bemiparin Sodium binds to antithrombin III, enhancing its inhibitory activity primarily against factor Xa and, to a lesser extent, factor IIa (thrombin). This accelerated inhibition disrupts the conversion of prothrombin to thrombin and the generation of fibrin, thereby interrupting the coagulation cascade and preventing the development and propagation of thrombi. The effect is dose‑dependent and provides a predictable anticoagulant response with a reduced need for routine laboratory monitoring compared with unfractionated heparin.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the subcutaneous injection area.
• Minor bleeding or bruising: easy bruising, nosebleeds, or gum bleeding.
• Nausea or dyspepsia: occasional gastrointestinal upset.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening bleeding requiring medical intervention.
• Thrombocytopenia (heparin‑induced): significant drop in platelet count that may lead to clotting.
• Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.
• Severe allergic reaction: anaphylaxis or angioedema.

When using Bemiparin Sodium, clinicians should observe specific precautions to ensure safe therapy.

• Renal function assessment: adjust use in patients with severe renal impairment.
• Bleeding risk evaluation: avoid in individuals with active uncontrolled bleeding.
• Concomitant anticoagulants: monitor closely when combined with other antithrombotic agents.
• Surgical procedures: discontinue before major surgery according to clinical guidelines.
• Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly indicated.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bemiparin Sodium can interact with several medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Antiplatelet agents (e.g., clopidogrel, aspirin) at high doses: synergistic anticoagulation.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

• Thrombolytic therapy (e.g., alteplase): additive effect on clot dissolution.
• Certain antibiotics (e.g., quinolones) that affect platelet function: may increase bleeding.
• Herbal supplements (e.g., ginkgo, garlic): potential enhancement of anticoagulant activity.